EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
Feb 14, 2019
WATERTOWN, Mass. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal period ended December 31, 2018 on Thursday, March
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
Feb 13, 2019
– Provides support for the product launches of YUTIQ™ and DEXYCU™ – WATERTOWN, Mass. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
Feb 04, 2019
- YUTIQ Indicated for the Treatment of Chronic Non-Infectious Posterior Segment Uveitis - WATERTOWN, Mass. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
Jan 28, 2019
– Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for Ocular Diseases - WATERTOWN, Mass. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to
EyePoint Pharmaceuticals Provides 2019 Commercial Update
Jan 03, 2019
- DEXYCU TM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQ TM commercial launch on track for 1Q19 -  WATERTOWN, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) --   EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing
EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
Dec 17, 2018
WATERTOWN, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
Nov 27, 2018
- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
Nov 12, 2018
WATERTOWN, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned
EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Nov 06, 2018
WATERTOWN, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
Nov 06, 2018
-YUTIQ ™ approved by U.S. FDA ; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ technology for posterior segment uveitis in Greater China - -Commercial preparations
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
Nov 05, 2018
WATERTOWN, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the
EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information
Oct 30, 2018
WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter of fiscal year 2019 on Tuesday, November 6 .
EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors
Oct 30, 2018
- Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
Oct 29, 2018
WATERTOWN, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data supporting the
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
Oct 18, 2018
- Five oral abstracts to be presented at annual meeting and subspecialty days – -24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
Oct 15, 2018
- The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S.  - Company to host conference call today at 8:30 a.m. ET WATERTOWN, Mass. , Oct.
EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
Oct 01, 2018
WATERTOWN, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
Sep 12, 2018

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of calendar year 2019 -Balance sheet strengthened by $35 million of capital led by EW

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
Sep 10, 2018
WATERTOWN, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its
EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
Sep 05, 2018
WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved
Displaying 21 - 40 of 353
EyePoint Pharmaceuticals